Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Burkitt Lymphoma 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Large B-Cell, Diffuse 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Prostatic Neoplasms 2Melanoma 2Lymphoma, Follicular 2Carcinoma, Merkel Cell 2Carcinoma, Basal Cell 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Plasmablastic Lymphoma 1Multiple Myeloma 1Lymphoma, Primary Effusion 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, AIDS-Related 1Lymphoma 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Leukemia, Biphenotypic, Acute 1HTLV-I Infections 1HIV Infections 1Down Syndrome 1Ann Arbor Stage II Mantle Cell Lymphoma 1

Interventions

pegaspargase 2merphos 2dexamethasone acetate 2dexamethasone 21-phosphate 2blinatumomab 2azathiopurine 2auricularum 2Vincristine 2N,N-dicyclohexyl-isoborneol-10-sulfonamide 2Methotrexate 2Mercaptopurine 2Dexamethasone 2Cytarabine 2Calcium Dobesilate 2Asparaginase 2prednylidene 1hydrocortisone hemisuccinate 1deltacortene 1calaspargase pegol 1asparaginase erwinia chrysanthemi recombinant 1Thioguanine 1Spinal Puncture 1Specimen Handling 1Radiotherapy, Conformal 1Radiotherapy 1Radiation 1Prednisone 1Prednisolone 1Nivolumab 1Methylprednisolone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Down Syndrome × deltacortene × Clear all
NCT03914625 2026-05-27

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
6,720 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡